Followers | 155 |
Posts | 12584 |
Boards Moderated | 0 |
Alias Born | 12/29/2013 |
Monday, May 27, 2019 3:55:57 PM
https://www.medicaldevice-network.com/news/creative-medical-technology-holdings-reveals-stem-cell-product-success/?fbclid=IwAR10fLmv5Is-iW3_ovf09dOXP53F3I6KU_tPE3hvKvsgv4-Eff_Mjyd90mA
Biotechnology company Creative Medical Technology Holdings has announced new data which demonstrates the superior immune modulatory ability of its AmnioStem stem cell product when compared to other stem cell types.
The company compared its product to bone marrow, adipose tissue, and placental tissue mesenchymal stem cells. The data generated at its BioLabs research facility in San Diego showed that AmnioStem cells were superior at suppressing production of inflammatory mediators such as TNF-alpha, interferon gamma, and interleukin-12.
Creative Medical Technology Holdings co-founder and chief scientific officer Dr Thomas Ichim said: “Control of molecules such as TNF-alpha represents a multi-billion dollar market. Currently drugs like Humira, Remicade, and Embrel, which are antibodies blocking the TNF-alpha pathway, have sales of over $30bn per year.
“Using cells as drugs represents a more viable alternative to existing approaches because the stem cells not only reduce inflammation, but also have ability to induce healing of injured tissue.”
Ichim has overseen the FDA clearance and clinical trials of several cell therapies. Creative Medical Technology Holdings is currently preparing an Investigational New Drug application with the FDA for use of its AmnioStem stem cell product for treatment of radiation toxicity.
The company’s president and CEO Timothy Warbington said: “We are extremely excited about our data, which positions Creative Medical Technology Holdings as a force in the autoimmune market.
“In addition to treatment of stroke and radiation toxicity, autoimmune diseases that may benefit from use of AmnioStem technology include Type 1 diabetes, rheumatoid arthritis, multiple sclerosis, and lupus.
“I am thankful for our collaborative network of scientists, scientific advisors, and intellectual property advisors, which are currently working in expanding the intellectual property portfolio surrounding this new cell type.”
The AmnioStem stem cell is covered by an issued US Patent, exclusively licensed from the University of California by the company in 2016.
Recent CELZ News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM